Rise above cholestatic pruritus (itch) in Alagille syndrome to


Hear From Real People Taking LIVMARLI
Watch Videos

LIVMARLI is FDA approved for the treatment of cholestatic pruritus (itch) in patients with Alagille syndrome who are 3 months of age and older.

LIVMARLI Can Help You  RISE ABOVE  Cholestatic Pruritus
Hourglass icon

More than 80% of patients experienced less itchiness than they felt at the start with LIVMARLI, with improvements seen as early as the very first assessment* and continued through the first year.

For patients who experienced a significant improvement in their itch—that is, more than a 1-point reduction in ItchRO(Obs)—93% were alive and did not have a liver transplant 6 years after starting LIVMARLI (please see important study design information in the Results With LIVMARLI section).

Shield icon

Backed by more than 5 years of data, LIVMARLI has a well-known safety record in patients with the itch in Alagille syndrome.

Over the last 6+ years, LIVMARLI has been used by 850+ patients to battle bile acid buildup.§

Conversation bubble icon

Approximately 94% of patients are approved for LIVMARLI by their insurance and 98% of patients pay $10 or less per fill.||¶

Mirum Access Plus offers resources, education, and services to help you start and stay on LIVMARLI.

*Itch relief was first assessed at Week 3.

Itch Reported Outcome for Observers (ItchRO[Obs]) is a tool designed for caregivers to measure itch severity over time.

From extended observation of patients taking LIVMARLI after completing a placebo-controlled study.

§Number includes all patients with cholestatic pruritus in Alagille syndrome treated with LIVMARLI in clinical studies, as well as those treated in the United States commercially and through the expanded access program.

||Data from 1/1/2022 to 12/31/2023.

Patients enrolled in the Mirum Patient Assistance Program are included in those paying $10 or less per fill.

Real patient and caregiver stories Real patient and caregiver stories

Hear from patients and families—and learn about the difference LIVMARLI has made in their lives.

Watch the Videos

Stay in the Know

To receive more information about LIVMARLI as it becomes available, please fill out the form below.


By completing this form, you agree to our Terms of Use and Privacy Policy.

Your sign-up was successful!

Be on the lookout for a welcome email from Mirum soon. Make sure to add livmarli-info@mirumpharma.com to your address book so that our emails go directly to your inbox.

We're having some connection trouble.

Refresh the page and try submitting your form again.

Note: This issue may occur if your email is already registered. Please check your inbox and spam folder to make sure you're receiving information. If the issue persists, please contact us.

Looks like this email is already registered.

Please check your inbox and spam folder to make sure you're receiving information.

New information is always sprouting up
expand btn collapse btn


LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients who are 3 months of age and older with Alagille syndrome.

It is not known if LIVMARLI is safe and effective in children with Alagille syndrome who are under 3 months of age. It is not known if LIVMARLI is safe and effective in adults who are 65 years of age and older.

Important Safety Information

What are the possible side effects 

  • Liver injury. Changes in certain liver tests are common in patients but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:
    • nausea or vomiting
    • your skin or the white part of your eye turns yellow
    • dark or brown urine
    • pain on the right side of your stomach (abdomen)
    • fullness, bloating, or fluid in your stomach area (ascites)
    • loss of appetite
    • bleeding or bruising more easily than normal, including vomiting blood
  • Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain during treatment. Diarrhea can also cause the loss of too much body fluid (severe dehydration). Your health care provider may advise you to monitor for new or worsening stomach problems, including stomach pain, diarrhea, blood in your stool, or vomiting. Tell your health care provider right away if you have any new or worsening signs or symptoms of stomach and intestinal problems, including:
    • diarrhea
    • more frequent bowel movements than usual
    • stools that are black, tarry, or sticky, or have blood or mucous
    • severe stomach-area pain or tenderness
    • vomiting
    • urinating less often than usual
    • dizziness
    • headache
  • A condition called Fat-Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment, and may monitor for bone fractures and bleeding, which are common side effects.

Tell your health care provider about all medicines that you take, as LIVMARLI may interact with other medicines. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.
Your health care provider may change your dose, or temporarily or permanently stop treatment if you have certain side effects.

LIVMARLI is taken by mouth, 1 time each day, 30 minutes before a meal in the morning. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.